Substandard rifampicin based anti-tuberculosis drugs common in Ugandan drug market

摘要

Tuberculosis (TB) is an important curable infectious disease in Uganda; its treatment however is facing a challenge of increasing drug resistance. Although rifampicin containing fixed-dose combination (R-FDC) drugs are a mainstay in TB treatment, about one fifth is reportedly substandard in the global drug market.? The aim of this study was to determine the quality of R-FDC and rifampicin single formulation anti-TB drugs in Kampala city, Uganda. Eight private and five public pharmacies were randomly selected, the drug samples were purchased and in the latter case obtained free of charge. Drug quality was assessed by visual inspection, weight uniformity, dissolution, and assay. Fifteen batches of anti-TB drugs were collected; 13 R-FDC and two rifampicin single dose formulations. One batch of R-FDC collected from a public pharmacy was not assayed as it had passed its expiry date by the time of analysis. Of the samples analyzed, six batches of R-FDC and two of rifampicin single dose formulations were purchased from private pharmacies. The other six batches of R-FDC were obtained from public pharmacies.? Ten samples (10/14: 71.4%) were not in the National Drug Register (NDR), eight of which were R-FDC and two rifampicin single dose formulations. Of the R-FDC drugs, four samples (4/12: 33.3%) failed the assay test and were all not in the NDR. All the R-FDC drug samples passed the dissolution, visual inspection and weight uniformity tests. All rifampicin single dose formulations passed assay, visual, and weight uniformity tests and only one failed the dissolution test. Unregistered and sub-standard rifampicin anti-TB drugs are common in drug outlets on the Ugandan drug market. These substandard drugs pose a risk to patients such as treatment failure that leads to increased cost of treatment and possibly loss of lives.